Skip to Content
Merck
All Photos(1)

Documents

V4262

Sigma-Aldrich

Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-1 antibody produced in mouse

clone FLT-11, ascites fluid

Synonym(s):

Anti-Flt1 Receptor, Anti-VEGF R-1

Sign Into View Organizational & Contract Pricing


About This Item

MDL number:
UNSPSC Code:
51111800
NACRES:
NA.41

biological source

mouse

Quality Level

conjugate

unconjugated

antibody form

ascites fluid

antibody product type

primary antibodies

clone

FLT-11, monoclonal

mol wt

antigen 160-200 kDa

contains

15 mM sodium azide

species reactivity

human

technique(s)

immunocytochemistry: suitable
immunohistochemistry (frozen sections): suitable
immunoprecipitation (IP): suitable
indirect ELISA: suitable
western blot: 1:500 using VEGF Receptor-1 (Flt-1)/Fc Chimera human recombinant

isotype

IgG1

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... FLT1(2321)

General description

Vascular Endothelial Growth Factor Receptor-2 (VEGF R2) is a 160-200kD protein that belongs to protein kinase superfamily and is expressed mainly on the surface of various endothelial cells. It plays a pivotal role in the regulation of angiogenesis, cell migration, cell survival and cancer cell invasion. ASV derived from VEGF receptor type 1 serve as a potential therapeutics for rheumatoid arthritis. Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-1antibody can be used in western blotting (diluted 1:500) using VEGF Receptor-1 (Flt-1)/Fc Chimera human recombinant. It can also be used in indirect ELISA. Mouse anti-Vascular Endothelial Growth Factor Receptor-1antibody reacts specifically with an epitope within amino acids 1-251 of the extracellular domain of human VEGF Receptor-1 but not with VEGF Receptor-2 (KDR). The product has shown cross reactivity with the mouse Flt1 receptor.
Vascular endothelial growth factor (VEGF) is also called vasculotropin (VAS) and vascular permeability factor (VPF). It is a homodimeric heparin-binding glycoprotein.

Specificity

Mouse monoclonal clone FLT-11 anti-VEGF R-1 antibody reacts specifically with the extracellular domain of human VEGF Receptor-1. The epitope recognized by the antibody resides within amino acid residues 1-251 of the VEGF Receptor-1 molecule. The product does not recognize VEGF Receptor-2 (KDR).

Immunogen

recombinant human VEGF-1 receptor.

Application

Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-1 antibody can be used in several immunochemical assays like immunohistochemistry, immunocytochemistry and immunoprecipitation for the localization of VEGF-R1.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Paul-Eduard Neagoe et al.
The Journal of biological chemistry, 280(11), 9904-9912 (2005-01-08)
We previously reported that vascular endothelial growth factor (VEGF)-A(165) inflammatory effect is mediated by acute platelet-activating factor synthesis from endothelial cells upon the activation of VEGF receptor-2 (VEGFR-2) and its coreceptor, neuropilin-1 (NRP-1). In addition, VEGF-A(165) promotes the release of
Tracey L Weissgerber et al.
The Journal of clinical endocrinology and metabolism, 99(3), 978-987 (2014-01-16)
Research examining the source of excess soluble fms-like tyrosine kinase 1 (sFLT1) in preeclampsia has focused on the placenta. The potential contribution of the releasable store of sFLT1 in the systemic vasculature is unknown. We asked whether the nonplacental releasable
Meiying Zhang et al.
Journal of ovarian research, 7, 19-19 (2014-02-11)
Tumor-associated macrophages (TAMs) are classified into two major phenotypes, M1 and M2. M1 TAMs suppress cancer progression, while M2 TAMs promote it. However, little is known regarding the role of TAMs in the development of ovarian cancer. Here, we investigated
Y K Y Lai et al.
Gene therapy, 9(12), 804-813 (2002-06-01)
Neovascularisation (NV) within the eye often results in visual loss. Vascular endothelial growth factor (VEGF) has been implicated in the development of ocular NV. Previous studies have shown that VEGF antagonists successfully suppressed retinal and choroidal NV in animal models.
A Rajakumar et al.
Placenta, 26(7), 563-573 (2005-07-05)
The soluble VEGF receptor, sFlt-1 (otherwise referred to as sVEGFR-1), has been implicated in the pathogenesis of preeclampsia. The preeclamptic placenta has been previously demonstrated to produce high levels of the soluble VEGF receptor. Here we tested the hypothesis that

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service